Fibrinogen - Octapharma
Alternative Names: Factor I concentrate-Octapharma; Fibrinogen (Human) Lyophilised Powder for Reconstitution; FIBRYGA; Fibryga; Fibryna; Human fibrinogen concentrate; OctafibrinLatest Information Update: 05 Aug 2024
Price :
$50 *
At a glance
- Originator Octapharma
- Developer Octapharma; University Health Network of Toronto
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Afibrinogenaemia
Most Recent Events
- 01 Aug 2024 US FDA grants expanded approval for Fibrinogen for Afibrinogenaemia
- 29 Mar 2021 Registered for Afibrinogenaemia (on-demand treatment of acute bleeding episodes) (In neonates, In infants) in USA (IV)
- 05 Dec 2020 Pooled efficacy and adverse events data from a phase III FORMA-02 and FORMA-04 trial in Congenital Fibrinogen Deficiency presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)